PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause?
Gettinger, Scott
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2016 - 4539-41 p. digital
Publication Type: Letter
1557-3265
10.1158/1078-0432.CCR-16-1401 doi
Anaplastic Lymphoma Kinase
Antineoplastic Agents--pharmacology
ErbB Receptors--genetics
Gene Rearrangement
Humans
Lung Neoplasms--drug therapy
Molecular Targeted Therapy
Mutation
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Receptor Protein-Tyrosine Kinases--genetics
Tumor Microenvironment--drug effects
PD-1 Axis Inhibitors in EGFR- and ALK-Driven Lung Cancer: Lost Cause? [electronic resource] - Clinical cancer research : an official journal of the American Association for Cancer Research Sep 2016 - 4539-41 p. digital
Publication Type: Letter
1557-3265
10.1158/1078-0432.CCR-16-1401 doi
Anaplastic Lymphoma Kinase
Antineoplastic Agents--pharmacology
ErbB Receptors--genetics
Gene Rearrangement
Humans
Lung Neoplasms--drug therapy
Molecular Targeted Therapy
Mutation
Programmed Cell Death 1 Receptor--antagonists & inhibitors
Receptor Protein-Tyrosine Kinases--genetics
Tumor Microenvironment--drug effects